There are currently 1011 clinical trials in Birmingham, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Alabama at Birmingham, University of Alabama, University of Alabama at Birmingham Cancer Center and University of Alabama Birmingham. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
NCT04266249
Recruiting
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or b... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
Register for Updates
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
NCT04323046
Recruiting
This phase I trial studies the side effects of nivolumab before and after surgery in treating children and young adults with high grade glioma that has come back (recurrent) or is increasing in scope or severity (progressive). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
All
Ages:
Between 6 months and 25 years
Trial Updated:
04/16/2024
Locations: University of Alabama at Birmingham, Children's of Alabama, Birmingham, Alabama
Conditions: Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Grade III Glioma, Grade III Glioma
Register for Updates
Assessment of CCM in HF With Higher Ejection Fraction
NCT05064709
Recruiting
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤60%.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: Grandview Medical Group Research, LLC, Birmingham, Alabama +1 locations
Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure
Register for Updates
Study of Tecovirimat for Human Monkeypox Virus
NCT05534984
Recruiting
A5418 is a randomized, placebo-controlled, double-blind study to establish the efficacy of tecovirimat for the treatment of people with laboratory-confirmed or presumptive HMPXV disease.
Gender:
All
Ages:
All
Trial Updated:
04/16/2024
Locations: Alabama CRS, Birmingham, Alabama
Conditions: Monkeypox, MPOX
Register for Updates
Amplatzer Amulet LAAO vs. NOAC
NCT04226547
Recruiting
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Cont... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: University Hospital - Univ. of Alabama at Birmingham (UAB), Birmingham, Alabama
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
NCT04042844
Recruiting
This is a double-blind, saline-controlled, and randomized study with blinded assessments using a single dose. Subjects that have a current diagnosis of chronic lumbar disc disease and meet eligibility criteria will be enrolled. Chronic lumbar disc disease is defined as back and/or radicular pain with degeneration of the disc confirmed by patient history, physical examination, and radiographic measures such as computed tomography (CT), magnetic resonance imaging (MRI), plain film, myelography, di... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
04/15/2024
Locations: Alabama Clinical Therapeutics, LLC, Birmingham, Alabama
Conditions: Lumbar Disc Disease
Register for Updates
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
NCT04485559
Recruiting
This phase I trial studies the side effects and best dose of trametinib and everolimus in treating pediatric and young adult patients with gliomas that have come back (recurrent). Trametinib acts by targeting a protein in cells called MEK and disrupting tumor growth. Everolimus is a drug that may block another pathway in tumor cells that can help tumors grow. Giving trametinib and everolimus may work better to treat low and high grade gliomas compared to trametinib or everolimus alone.
Gender:
All
Ages:
Between 1 year and 25 years
Trial Updated:
04/15/2024
Locations: University of Alabama at Birmingham, Children's of Alabama, Birmingham, Alabama
Conditions: Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High Grade Glioma
Register for Updates
Coaching Dementia Caregivers to Master Care-Resistant Behavior
NCT05098652
Recruiting
266 family caregivers will be randomly assigned to either immediate intervention or delayed intervention groups. All caregivers will complete baseline surveys and 3 weeks of daily diaries. The immediate intervention group will receive 12 weeks of CuRB-IT. They will complete 3 rounds of 3-week daily diaries followed by an intermittent survey at 12 week intervals for the next 33 weeks. The delayed intervention group will receive 12 weeks of attention, complete 1 round of 3-week daily diaries follo... Read More
Gender:
All
Ages:
Between 18 years and 95 years
Trial Updated:
04/15/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Care-resistant Behavior, Dementia
Register for Updates
Nutrition for Precision Health, Powered by the All of Us
NCT05701657
Recruiting
The goal of this investigational study is to develop algorithms that predict human response to foods. The main question it aims to answer are: How does varying foods and eating patterns impact one's biological and physiological responses? In what ways can novel dietary assessment measures be used to improve dietary assessments and to prescribe assessments to people in future research with increased precision? Can artificial intelligence and machine learning techniques be combined to prescribe f... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Nutrition, Health, Dietary Habits
Register for Updates
Optimizing Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome (OPTimize NOW): A Symptom-Based Dosing Approach
NCT05980260
Recruiting
This clinical trial will help us learn more about how to best care for babies with Neonatal Opioid Withdrawal Syndrome, also called NOWS. Babies with NOWS often have tremors, a hard time sleeping, excessive crying, and trouble feeding. Some babies that have NOWS need medicine. Doctors have two ways of providing medicine that are widely used today: Scheduled opioid taper approach. The baby gets medicine at regular times. As symptoms get better, the amount of medicine the baby gets decreases unti... Read More
Gender:
All
Ages:
Between 1 hour and 48 hours
Trial Updated:
04/15/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Neonatal Opiate Withdrawal Syndrome
Register for Updates
A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients
NCT04075916
Recruiting
The Transplanting Hepatitis C Kidneys into Negative KidnEy Recipients [THINKER-NEXT] study will include adult kidney transplant candidates without hepatitis C virus (HCV) infection on the transplant waiting list who will consent to kidney transplantation from a deceased donor infected with HCV, followed by treatment with a direct acting antiviral. The one-year allograft function and one-year risk of CMV infection will be compared between THINKER-NEXT kidney transplant recipients and matched reci... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: End Stage Renal Disease
Register for Updates
Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation
NCT06169735
Recruiting
The aim of this study is to determine if fluorescence with or without indocyanine green can facilitate safe and accurate thyroid and parathyroid surgery.
Gender:
All
Ages:
19 years and above
Trial Updated:
04/15/2024
Locations: UAB Callahan Eye, Birmingham, Alabama
Conditions: Parathyroid Dysfunction, Adenoma
Register for Updates